tert-Butyl 4-(5-nitropyridin-2-yl)piperazine-1-carboxylate

Catalog No. :
ACOHEC495
CAS No. :
193902-78-2
Molecular Formula :
C14H20N4O4
Molecular Weight :
308.34

IUPAC Name:tert-butyl 4-(5-nitropyridin-2-yl)piperazine-1-carboxylate

tert-Butyl 4-(5-nitropyridin-2-yl)piperazine-1-carboxylate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-Butyl 4-(5-nitropyridin-2-yl)piperazine-1-carboxylate
IUPAC Nametert-butyl 4-(5-nitropyridin-2-yl)piperazine-1-carboxylate
MDL No.MFCD07369779
Molecular FormulaC14H20N4O4
Molecular Weight308.34
SMILESO=C(N1CCN(C2=NC=C([N+]([O-])=O)C=C2)CC1)OC(C)(C)C
InChI KeyWWFJYZONBJARJT-UHFFFAOYSA-N
SynonymYSZC2054 | DS-2660 | SCHEMBL594287 | 1-Boc-4-(5-nitro-2-pyridyl)piperazine, 97% | J-012555 | MFCD07369779 | 1-(terbutyloxycarbonyl)-4-(5-nitro-piridin-2-yl)-piperazine | AKOS005106668 | AKOS034830282 | A880232 | WWFJYZONBJARJT-UHFFFAOYSA-N | 1-Piperazinec
CAS No.193902-78-2
PubChem CID16217943

Safety Data

Pictogram
Toxic
Signal Word
Gefahr
Hazard Statement(s)
H301-H319
Precautionary Statement(s)
P301+P310-P305+P351+P338

Synthetic Route by SureRoute

1. ACOHEC495 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACBRWP053 route compound structure diagram
    ACBRWP05357260-72-7 In Stock
  2. Plus
  3. ACIQZE135 route compound structure diagram
    ACIQZE1354548-45-2 In Stock
  4. Then
  5. ACOHEC495 route product structure diagram
    ACOHEC495193902-78-2
Inquiry

2. ACOHEC495 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACBRWP053 route compound structure diagram
    ACBRWP05357260-72-7 In Stock
  2. Plus
  3. ACCMJE890 route compound structure diagram
    ACCMJE8904487-59-6 In Stock
  4. Then
  5. ACOHEC495 route product structure diagram
    ACOHEC495193902-78-2
Inquiry

Comments (0)